Advanced Enzyme Technologies Ltd · NSE:ADVENZYMES
Advanced Enzyme Technologies — Q4 FY2020 Earnings Presentation
14 slides from Advanced Enzyme Technologies's earnings presentation, May 30, 2020
Slide 1: Advanced Enzyme Technologies Limited Earnings Presentation Q4FY20
Where ENZYME is Life 2 Advanced Enzyme Technologies Limited Earnings Presentation | Q4FY20
Slide 2: Disclaimer
Disclaimer This information may contain certain forward‐looking statements/details in the current scenario, which is extremely dynamic and increasingly fraught with risks and uncertainties. Actual results, performances, achievements or sequence of events may be materially different from the views ex
Slide 3: Company Overview
Company Overview What are enzymes? Enzymes are natural protein molecules that act as catalysts within living cells, produced by all living organisms. Function as specialized catalysts and accelerate the pace of biochemical reactions. Advanced uses enzymes to replace chemicals in, and improve efficie
Slide 4: A Rising Global Star
Advanced Enzyme Technologies Limited – A Rising Global Star Manufacturing Units – 7 R&D Units – 7 } India – 4 | USA – 1 | Germany – 2 India ‐ 5 USA ‐ 2 REVENUE (₹ mn) 1st 2nd 2nd 4,440 Indian enzyme company Highest market share in India Listed integrated enzyme 2,938 player globally FY 16 FY 20 EBID
Slide 5: Results Summary – Q4FY20 (Consolidated)
Results Summary – Q4FY20 (Consolidated) *Revenue (₹ mn) EBITDA (₹ mn) PAT (₹ mn) 1,104 1,103 335 327 497 487 Q4FY19 Q4FY20 Q4FY19 Q4FY20 Q4FY19 Q4FY20 Revenue Breakup ₹ in Million *YoY Growth Animal HC Human HC Industrial Processing -24% Q4FY20 126 6% Q4FY20 779 Q4FY20 (1%) 190 Q4FY19 121 Q4FY19 832
Slide 6: Revenue Split – Q4FY20
Revenue Split – Q4FY20 Q4FY20 Q4FY19 Segmental Revenue Split (%) Segmental Revenue Split (%) 17% 12% 14% 11% 71% 75% Animal HC Human HC Bio‐Processing Animal HC Human HC Bio‐Processing Geographical Revenue Split (%) Geographical Revenue Split (%) 3% 1% 7% 5% 38% 46% 42% 43% 9% 6% Asia (ex‐ India) Ot
Slide 7: Results Summary – FY20
Results Summary – FY20 Revenue (₹ mn) EBITDA (₹ mn) PAT (₹ mn) 4,440 2,023 1,159 1,330 4,196 1,819 FY19 FY20 FY19 FY20 FY19 FY20 Revenue Breakup ₹ in Million *YoY Growth Animal HC Human HC Industrial Processing -24% FY20 536 FY20 3,211 FY20 555 (1%) FY19 493 FY19 3,133 FY19 512 9% 2% 8% Note: 1. On
Slide 8: Revenue Split – FY20
Revenue Split – FY20 FY20 FY19 Segmental Revenue Split (%) Segmental Revenue Split (%) 13% 12% 12% 12% 75% 76% Animal HC Human HC Bio‐Processing Animal HC Human HC Bio‐Processing Geographical Revenue Split (%) Geographical Revenue Split (%) 2% 2% 6% 4% 42% 49% 40% 43% 7% 5% Asia (ex‐ India) Others I
Slide 9: Profit & Loss (Consolidated) – Q4FY20 & FY20
Profit & Loss (Consolidated) – Q4FY20 & FY20 ₹ in Million except per share data Q4FY20 Q3FY20 Q4FY19 FY20 FY19 Particulars Y‐o‐Y (%) Y‐o‐Y (%) Audited Unaudited Audited Audited Audited Income from Operations 1,103 1,119 1,104 0% 4,440 4,196 6% Expenses 682 655 659 3% 2,675 2,587 3% Profit from Opera
Slide 10: Balance Sheet (Consolidated) – FY20
Balance Sheet (Consolidated) – FY20 ₹ in Million FY20 FY19 Particulars Audited Audited Assets Property, plant and equipment 2,042 1,618 Capital work‐in‐progress 101 105 Intangible assets 646 622 Goodwill 2,941 2,715 Other non‐current assets 195 183 Current assets 3,813 2,820 Assets held for sale 48
Slide 11: Strong Financial Performance – FY20
Strong Financial Performance – FY20 ₹ in Million Revenue from Operations EBIDTA & EBIDTA Margin (%) 4,440 2,500 47% 43% 46% 50% 3,957 4,196 42% 48% 45% 2,000 3,431 46% 2,938 1,500 1,654 44% 1,534 2,023 1,000 1,389 42% 1,819 40% 500 38% 0 36% FY 16 FY 17 FY 18 FY 19 FY 20 FY 16 FY 17 FY 18 FY 19 FY 2
Slide 12: Strong Financial Performance – FY20
Strong Financial Performance – FY20 Net Working Capital (Days) Net Worth (₹ mn) 8,396 119 6,788 115 5,591 112 4,640 108 105 2,781 FY 16 FY 17 FY 18 FY 19 FY 20 FY 16 FY 17 FY 18 FY 19 FY 20 ROE (%) & ROCE (%) Net Debt to Equity (x) 34% 0.4 27% 27% 24% 21% 28% 19% 18% 19% 0.1 16% 0.01 0.02 0.00 FY 16
Slide 13: Shareholder Information
Shareholder Information Top 5 Institutional Holders (As on 22th May 2020) Stock Data (As on 29th May 2020) Institutions OS (%) ORBIMED ASIA III MAURITIUS 12.09 Market Capitalization (₹) 16,738 mn HDFC TRUSTEE COMPANY LTD. 7.01 Shares Outstanding 111.64 mn RELIANCE CAPITAL TRUSTEE CO. 1.42 Free Float
Slide 14: Thank You
Advanced Enzyme Technologies Limited Address: 5th Floor, 'A' wing, Sun Magnetica LIC Service Road, Louiswadi, Thane (W) 400 604, India Tel: +91‐22‐4170 3200 Web: www.advancedenzymes.com Fax: + 91‐22‐25835159 Thank You
Advanced Enzyme Technologies — Q4 FY2020 Earnings Presentation on 6ix